The treatment of elderly patients with chronic lymphocytic leukemia and comorbid conditions requires an assessment of individual patient factors an......READ MORE
by Jennifer R. Brown, MD, PhD; Anthony Mato, MD, MSCE; and Susan O’Brien, MD
The most appropriate way to combine and/or sequence the novel agents remains to be determined; however, an abundance of data support the use of ibr......READ MORE
by Jennifer R. Brown, MD, PhD; Anthony Mato, MD, MSCE; and Susan O’Brien, MD
17p deletion (del[17p]) and/or aberrant TP53 have historically been considered high-risk categories in patients with chronic lymphocytic leukemia (......READ MORE
clinical topic updates by Jennifer R. Brown, MD, PhD; Anthony Mato, MD, MSCE; and Susan O’Brien, MD
Richter transformation (RT) represents a spectrum of disease that can involve progression to a number of hematologic diseases. Recent evidence sugg......READ MORE
Treatments for chronic lymphocytic leukemia (CLL) vary in efficacy, safety, routes of administration, and cost. With an increasing number of availa......READ MORE
Based on the available data, patients with chronic lymphocytic leukemia (CLL) being treated with novel agents such as ibrutinib or venetoclax can b......READ MORE
